Article
Efalizumab (Raptiva), an investigational therapy for moderate-to-severe psoriasis, achieved its primary efficacy endpoint in a randomized phase III study.
Nutraceuticals: A Boost for Skin Health
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
What’s Next for Topical JAK Inhibitors?
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Day 1 Recap: SBS 2025
Tips and Tricks for Successful Practice Management with Leon Kircik, MD